Walgreens profit beats estimates on PBM partnerships
The exterior of the Walgreens store in Times Square is seen in New York, U.S., July 5, 2016. Picture taken July 5, 2016. REUTERS/Shannon Stapleton
Get Alerts WBA Hot Sheet
Join SI Premium – FREE
(Reuters) - Walgreens Boots Alliance Inc (NASDAQ: WBA) reported a better-than-expected quarterly profit as recent partnerships with pharmacy benefit managers (PBMs) and insurance companies helped boost sales of prescription drugs as well as non-drug items.
The largest U.S. drugstore chain also raised the lower end of its adjusted profit forecast for the year ending August 2017.
Walgreens, which is awaiting regulatory approval for its $9.5 billion takeover of smaller rival Rite Aid Corp (NYSE: RAD), said it expects to close the deal early this year.
It had previously extended the merger agreement till Jan. 27.
Walgreens entered partnerships last year with PBMs such as Express Scripts Holding Co (NASDAQ: ESRX) and OptumRx and insurer UnitedHealthcare (NYSE: UNH) which helped boost sales in the first quarter.
Net income attributable to Walgreens fell to $1.05 billion, or 97 cents per share, in the first quarter ended Nov. 30, from $1.11 billion, or $1.01 per share, a year earlier.
Excluding items, the company earned $1.10 per share, beating the average analysts' estimate of $1.09, according to Thomson Reuters I/B/E/S.
Sales fell to $28.50 billion from $29.03 billion, falling for the first time in four years and missing the analyst estimate of $29.23 billion.
(Reporting by Sruthi Ramakrishnan in Bengaluru; Editing by Shounak Dasgupta)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SpaceX bond sale draws $89 billion in investor demand
- Analysis-Alo Yoga primed for public offering or sale after owner's sale of wholesale T-shirt business
- Soccer-U.S. look to keep World Cup momentum going against eliminated Turkey
Create E-mail Alert Related Categories
ReutersRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share